BK virus associated nephropathy
Conditions
Interventions
Conversion From Tacrolimus To Lower-Dose Cyclosporine:Tac was switch to CsA (150-200mg/d) with target trough concentration of 70-110 ng/ml
Reduction Of Tacrolimus:Tac dosage was reduced by 25-50% with target trough concentration of 4-6 ng/ml
Sponsors
The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Diagnosed as BKVN by kidney biopsy and serum creatinine less than 300 umol/L; 2) Receiving tacrolimus, MMF and corticosteroid as primary immunosuppressant regimen; 3) Willing to sign in the informed consent and having good compliance.
Exclusion criteria
Exclusion criteria: 1) Enrolling for another clinical study; 2) Suffering from mental illness or having difficulties to comprehend the trial; 3) Being unsuitable for participating in this trial in the opinion of investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum creatinine;centration;BKV-DNA in plasma;BKV-DNA in urine;Decoy cell;Kidney biopsy;Incidence of acute rejection; | — |
Secondary
| Measure | Time frame |
|---|---|
| Urine protein;Other side effects; | — |
Countries
China
Contacts
Public ContactHuang Gang
Department of Organ Transplantation, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
Outcome results
None listed